🔴 High ImpactPharma
Suven Life Sciences advances SUVN-I6107 to Phase-2 after successful FIH trial
Suven Life Sciences advances SUVN-I6107 to Phase-2 after successful FIH trial — Suven Life Sciences announced the successful completion of the First-in-Human Phase-1 trial of SUVN-I6107, a novel M1-PAM for cognitive disorders. Positive topline results support advancement into Phase-2 clinical development. This milestone validates the drug’s safety and pharmacokinetic profile. \n\n 📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #HIGHIMPACT #ClinicalTrial
#ClinicalTrial#Pharma#R&D#Phase2
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →